May 11, 2020 09:33 AM EDT
R&D
FDA+

De­railed by the pan­dem­ic, FDA of­fers CRISPR, Ver­tex drug pro­gram VIP sta­tus for its come­back play

John Carroll

Editor & Founder

CRISPR Ther­a­peu­tics may have run in­to a hur­dle for its clin­i­cal pro­gram to ad­vance CTX001 in se­vere he­mo­glo­binopathies, but the FDA is on record that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times